Bleeding pattern in combined oral contraceptive (ethinylestradiol 35 μg/norgestimate 250 μg) users: Influence of regularity of use and start day in the first cycle;Výskyt krvácení u uživatelek kombinované hormonální antikoncepce (etinylestradiol 35 μg/norgestimát 250 μg) v závislosti na pravidelnosti a způsobu zahájení užívání

Ceska Gynekologie

Volumn 68, Issue 2, 2003, Pages 84-88

  Pasekova V ^a,c   Chroust, K ^b  

^a Sanatorium Repromeda   (Czech Republic)

^b MASARYK UNIVERSITY   (Czech Republic)

^c NONE   (Czech Republic)

Author keywords

Cycle control; Ethinylestradiol; Norgestimate; Oral contraceptives; Sunday start

Indexed keywords

ETHINYLESTRADIOL PLUS NORGESTIMATE; ORAL CONTRACEPTIVE AGENT;

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY WEIGHT; BREAKTHROUGH BLEEDING; CHRONOTHERAPY; CLINICAL TRIAL; DOSE TIME EFFECT RELATION; DRUG USE; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD; MENSTRUAL CYCLE; MENSTRUAL IRREGULARITY; MULTICENTER STUDY; ORAL CONTRACEPTION; SIDE EFFECT; VAGINA BLEEDING;

ADOLESCENT; ADULT; CONTRACEPTIVES, ORAL, HORMONAL; ETHINYL ESTRADIOL-NORGESTREL COMBINATION; FEMALE; HUMANS; MIDDLE AGED; PATIENT COMPLIANCE; PROSPECTIVE STUDIES; UTERINE HEMORRHAGE;

EID: 0347294782     PISSN: 12107832     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Andolsek, K. M.: Cycle control with triphasic norgestimate and ethinyl estradiol, a new oral contraceptive agent. Acta Obstet. Gynec. Scand., 1992, 71, suppl. 156, s. 22-26.
2. nd ed. Edinburgh: Chirchill Livingstone, 1993, s. 119.
3. st ed. Edinburgh: Churchill Livingstone, 1994, s. 89.
4. Korver, T., Goorissen, E., Guillebaud, J.: The combined oral contraceptive pill: what advice should we give when tablets are missed? Br. J. Obstet. Gynaec., 102, 1995, s. 601-607.
5. Notelovitz, M.: Contraceptive efficacy and safety of a monophasic oral contraceptive containing 150 micrograms desogestrel and 30 micrograms ethinyl estradiol: United States clinical experience using a"Sunday start" approach. Fertil. Steril., 64, 1995, 2, s. 261-266.
6. Paseka, J., Unzeitig, V., Hořejší, J., Rotta, L., Chroust, K., Cibula, D.: Klinická studie s třífázovým antikoncepčním přípravkem (norgestimát 180/215/215 μg + etinylestradiol 35 μg) v populaci ćeských žen. Čes. Gynek., 64, 1999, s. 246-254.
7. Rosenberg, M. J., Waugh, M. S., Higgins, J. E.: The Effect of Desogestrel, Gestodene, and Other Factors on Spotting and Bleeding. Contraception, 53, 1996, s. 58-90.
8. Rosenberg, M. J., Waugh, M. S.: Oral contraceptive discontinuation: A prospective evaluation of frequency and reasons. Am. J. Obstet. Gynec., 179, 1998, s. 577-82.
9. Rosenberg, M. J., Waugh, M. S.: Causes and consequences of oral contraceptive noncompliance. Am. J. Obstet. Gynec., 180(2 Pt 2), 1999, s. 276-279.
10. Runnebaum, B., Grunwald, K., Rabe, T.: The efficacy and tolerability of norgestimate/ethinyl estradiol (250 μ of norgestimate/35 μg ethinyl estradiol): Results of an open, multicenter studiy of 59,701 women. Am. J. Obstet. Gynec., 166, 1992, s. 1963-1968.